Iguana Healthcare Management LLC bought a new position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 60,000 shares of the biopharmaceutical company’s stock, valued at approximately $905,000.
Other institutional investors also recently made changes to their positions in the company. Strs Ohio bought a new stake in Amicus Therapeutics during the third quarter worth approximately $102,000. Birchview Capital LP bought a new stake in Amicus Therapeutics during the third quarter worth approximately $151,000. Teacher Retirement System of Texas boosted its position in Amicus Therapeutics by 1.7% during the second quarter. Teacher Retirement System of Texas now owns 10,243 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 169 shares during the period. Engineers Gate Manager LP bought a new stake in Amicus Therapeutics during the third quarter worth approximately $155,000. Finally, Tudor Investment Corp ET AL bought a new stake in Amicus Therapeutics during the second quarter worth approximately $124,000.
FOLD has been the subject of a number of recent analyst reports. J P Morgan Chase & Co reaffirmed an “overweight” rating on shares of Amicus Therapeutics in a research report on Wednesday, October 4th. Chardan Capital reaffirmed a “buy” rating and set a $16.50 target price (down previously from $17.50) on shares of Amicus Therapeutics in a research report on Wednesday, September 13th. Zacks Investment Research raised Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 target price for the company in a research report on Tuesday, October 10th. Cowen reaffirmed an “outperform” rating and set a $18.00 target price (up previously from $16.00) on shares of Amicus Therapeutics in a research report on Thursday, September 14th. Finally, Robert W. Baird reissued an “outperform” rating and issued a $18.00 price objective (up from $16.00) on shares of Amicus Therapeutics in a research report on Wednesday, October 4th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $17.81.
Shares of Amicus Therapeutics, Inc. (NASDAQ FOLD) opened at $12.90 on Friday. Amicus Therapeutics, Inc. has a 12-month low of $4.41 and a 12-month high of $16.60. The company has a debt-to-equity ratio of 0.39, a quick ratio of 6.22 and a current ratio of 6.32.
Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.10). Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. The business had revenue of $10.90 million during the quarter, compared to the consensus estimate of $9.02 million. During the same period in the prior year, the company posted ($0.33) earnings per share. The firm’s revenue was up 419.0% compared to the same quarter last year. analysts anticipate that Amicus Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.